Contribute Try STAT+ Today

WASHINGTON — The beleaguered pharmaceutical industry’s top lobbying group spent about $8 million to influence the federal government during the first quarter of 2017, a roughly 33 percent hike over last year at this time — and its biggest expansion in at least five years.

The surge is not a surprise. Earlier this year, a lobbyist for the Pharmaceutical Research and Manufacturers of America, PhRMA, told STAT they planned to donate less and lobby more. They also raised their members’ dues to pay for more lobbying power.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy